• Our People
  • Global Presence
  • Regions
    • Asia
    • Europe
    • Americas
  • Offices
    • Canada
      • Ottawa
      • Toronto
    • China
      • Beijing
      • Hong Kong
    • France
      • Paris
      • Sophia Antipolis
    • Luxembourg
    • Malaysia
    • Singapore
    • UK
      • Aberdeen
      • Birmingham
      • Cambridge
      • Edinburgh
      • Glasgow
      • London
      • Manchester
      • Oxford
  • Client liaison
    • Japan
    • Korea
  • Expertise
  • Services
    • Patents
    • Brands & Trade Marks
    • Designs
    • Litigation & Dispute Resolution
    • Commercial IP & Contracts
    • Due Diligence
    • Freedom to Operate
    • EPO Patent Oppositions
    • European Patent Validations
    • Anti-counterfeiting
    • Open Source & Third Party Code
  • Sectors
    • Energy & Environment
    • Life Sciences
    • Agritech
    • Medical Technologies
    • Chemistry
    • Transport
    • Entertainment & Creative Industries
    • Food & Drink
    • Fashion & Retail
    • Universities & Research Bodies
    • Start-ups & Spin-outs
    • Digital Transformation
      • 3D Printing
      • Artificial Intelligence
      • Blockchain
      • Data & Connectivity
      • Extended Reality
      • Industry 4.0
  • About Us
    • Working with us
    • Awards
    • Corporate & Social Responsibility
    • Diversity & Inclusion
    • Careers
  • Insights
    • M&C Reacts
    • Beyond Brexit - UK & EU trade marks
    • Covid-19
    • Unitary Patent & Unified Patent Court
    • All publications
  • Contact Us
Marks & Clerk logo (magenta)
Marks & Clerk logo (magenta)
Contact Us
Language
English
Our People
Global Presence
Regions
  • Asia
  • Europe
  • Americas
Offices
  • Canada
    • Ottawa
    • Toronto
  • China
    • Beijing
    • Hong Kong
  • France
    • Paris
    • Sophia Antipolis
  • Luxembourg
  • Malaysia
  • Singapore
  • UK
    • Aberdeen
    • Birmingham
    • Cambridge
    • Edinburgh
    • Glasgow
    • London
    • Manchester
    • Oxford
Client liaison
  • Japan
  • Korea
Expertise
Services
  • Patents
  • Brands & Trade Marks
  • Designs
  • Litigation & Dispute Resolution
  • Commercial IP & Contracts
  • Due Diligence
  • Freedom to Operate
  • EPO Patent Oppositions
  • European Patent Validations
  • Anti-counterfeiting
  • Open Source & Third Party Code
Sectors
  • Energy & Environment
  • Life Sciences
  • Agritech
  • Medical Technologies
  • Chemistry
  • Transport
  • Entertainment & Creative Industries
  • Food & Drink
  • Fashion & Retail
  • Universities & Research Bodies
  • Start-ups & Spin-outs
  • Digital Transformation
    • 3D Printing
    • Artificial Intelligence
    • Blockchain
    • Data & Connectivity
    • Extended Reality
    • Industry 4.0
About Us
  • Working with us
  • Awards
  • Corporate & Social Responsibility
  • Diversity & Inclusion
  • Careers
Insights
  • M&C Reacts
  • Beyond Brexit - UK & EU trade marks
  • Covid-19
  • Unitary Patent & Unified Patent Court
  • All publications

Richard Gibbs

Partner

Europe
Glasgow

Get in contact

+44 141 221 5767 rgibbs@marks-clerk.com
vCard

Richard advises clients in patenting and other IP matters in the field of biotechnology and has particular expertise in technologies relating to antibodies, vaccines, biologics, virology, bacteriology and molecular biology. He has worked with all of Scotland’s major universities and is a regular speaker at IP conferences and events.

Richard joined the patent profession after a period as both a research scientist and a university lecturer having obtained an honours degree in medical microbiology and a doctorate in immunology and microbiology from the University of Edinburgh.

Richard is mentioned by Managing Intellectual Property’s IP Stars which says he is “recommended for life sciences patent work”.

Languages

  • English

Specialist in

  • Patents
  • Due diligence
  • Chemistry
  • Medical technologies

Qualifications

BSc, PhD

Search our people

Latest Insights

EPO
Insight
- 07 April 2022

To be (amended) or not to be (amended)…what is the answer?

Two recently issued and differing decisions have muddled what used to be a routine, albeit peculiar, part of European patent prosecution. Having successfully prosecuted your claims before the EPO, should you adhere to an examiner’s request to amend your description or not? That is, all of a sudden, a tricky question!
Read more
Marks & Clerk logo (white)
  • Terms & Conditions
  • Privacy Notice
  • Cookies
  • Legal Notices
  • Lexology
  • Mondaq